Half-Life of Risperidone (Risperdal)
The elimination half-life of oral risperidone is approximately 20 hours for the active moiety (risperidone plus 9-hydroxyrisperidone combined), while the long-acting injectable depot formulation has a half-life of 3-6 days. 1, 2
Immediate-Release Oral Formulation
The half-life of oral risperidone varies significantly based on CYP2D6 metabolizer status:
- Extensive metabolizers (most patients): Risperidone alone has a half-life of approximately 3 hours, while the active metabolite 9-hydroxyrisperidone has a half-life of about 21 hours 1
- Poor metabolizers (6-8% of Caucasians): Risperidone alone has a prolonged half-life of approximately 20 hours, while 9-hydroxyrisperidone has a half-life of about 30 hours 1
- Active moiety (clinically relevant): The combined half-life of risperidone plus 9-hydroxyrisperidone is approximately 20 hours in both extensive and poor metabolizers, making this the most clinically meaningful parameter 1, 3, 4
Key Clinical Implications for Oral Formulation:
- Steady-state is reached within 1 day for risperidone and within 5 days for the active fraction 4
- The 20-hour half-life of the active moiety supports twice-daily or potentially once-daily dosing 5
- CYP2D6 polymorphism has minimal impact on clinical efficacy because the metabolite 9-hydroxyrisperidone is equipotent to the parent drug 1, 3
Long-Acting Injectable (LAI) Depot Formulation
The pharmacokinetics of Risperdal Consta differ substantially from oral risperidone:
- Apparent half-life: 3-6 days, associated with monoexponential decline in plasma concentrations 2
- This prolonged half-life relates to the erosion of microspheres and subsequent absorption of risperidone, not the drug's intrinsic elimination 2, 6
- Significant release begins 3 weeks after the first injection, necessitating oral antipsychotic supplementation during this initial period 6
- Steady-state is reached after the fourth injection (approximately 8 weeks) 6
- Complete elimination occurs 7-8 weeks after the last injection 2, 6
Critical Pitfalls with LAI Formulation:
- Do not assume immediate therapeutic effect—the 3-week lag time requires bridging with oral antipsychotics 6
- When discontinuing, remember that drug effects persist for nearly 2 months after the final injection 2
- No accumulation occurs with biweekly dosing at 25 mg or 50 mg over 12 months 2
Special Populations
Renal impairment: The half-life is prolonged due to 60% decreased clearance of the active moiety; dose reduction is required 1, 2
Hepatic impairment: While the half-life remains comparable, free fraction increases by 35%; dose reduction is recommended 1, 2
Elderly patients: Both risperidone and 9-hydroxyrisperidone show decreased renal clearance and prolonged elimination half-lives; dose modification is necessary 1